Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

Despite improvement in pathologic complete response with preoperative chemoradiation, the benefit did not extend to overall ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Speakers at the 2024 World Conference on Lung Cancer discussed the considerations that must go into designing and performing ...

Fig 1. Summary of key management of locally advanced rectal cancer guideline recommendations. The following recommendations (strong or conditional) represent reasonable options for patients depending ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Long-term outcomes in the ITT population as well as those receiving long-term exposure to tislelizumab plus chemotherapy as treatment for first line squamous NSCLC in RATIONALE-307 show a continued OS ...

who have not progressed following definitive platinum-based concurrent chemoradiation therapy (CRT) is ongoing. After the period, the Independent Data Monitoring Committee recommended the ...

Dr. Ballas concluded her presentation discussing whether clinical responders have an option for chemoradiation with the following take-home points: There is interest in neoadjuvant chemotherapy prior ...